Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg/day for patients not on CYP3A enzyme inducing anti-epileptic drugs (EIAEDs) and at 500 mg twice a day for patients on EIAEDs. The primary endpoint was progression-free survival at 6 months (PFS-6) and secondary endpoints were safety, radiographic response rate, and overall survival (OS). Best radiographic response was stable disease and was observed in 14 patients (67%). PFS-6 for all patients, those with grade I tumors (n = 8) and those with grade II or III tumors (n = 13) was 61.9, 87.5 and 46.2%, respectively. Patients with grade II or III tumors had poorer PFS and OS than those with grade I tumors, (P = 0.025 and P = 0.018) respectively. The only grade 3 or greater adverse event occurring in ≥ 10% of patients was anemia (10%). Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Pyrimidines
- Piperazines
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Neoplasm Grading
- Middle Aged
- Meningioma
- Meningeal Neoplasms
- Male
- Kaplan-Meier Estimate
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Pyrimidines
- Piperazines
- Oncology & Carcinogenesis
- Neoplasm Recurrence, Local
- Neoplasm Grading
- Middle Aged
- Meningioma
- Meningeal Neoplasms
- Male
- Kaplan-Meier Estimate